Physician profile
Jesse Astorga, III
NPI 1972119964
$8,824.41
in general payments reported to CMS, 2019-2025
31 companies · $3,007 in 2025
The $3,007 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,703 · 2022: $1,626 · 2023: $1,262 · 2024: $1,226 · 2025: $3,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.10 |
| Education | $135.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,464.39 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,261.79 | 2021-2025 | Dupixent |
| Genzyme Corporation | $753.04 | 2022-2025 | |
| Optinose US, INC. | $680.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $677.49 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $568.70 | 2021-2023 | Auvi-Q |
| Pfizer INC. | $521.44 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $478.74 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Novartis Pharmaceuticals Corporation | $322.66 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $322.32 | 2025 | Neffy |
| Csl Behring | $268.00 | 2024-2025 | Andembry, Haegarda, Hizentra |
| Galderma Laboratories, L.P. | $251.88 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $194.58 | 2021-2023 | |
| Genentech USA, INC. | $150.19 | 2021-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $139.29 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $124.25 | 2021 | |
| Leo Pharma INC. | $98.18 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.86 | 2021 | |
| Organon LLC | $85.06 | 2025 | Vtama |
| Incyte Corporation | $68.21 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $57.73 | 2025 | Zoryve |
| Amgen INC. | $51.55 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $37.39 | 2023-2024 | Ryaltris |
| Electromed, INC. | $32.32 | 2025 | Smartvest |
| Aimmune Therapeutics, INC. | $24.47 | 2021 | |
| Insmed, INC. | $22.17 | 2025 | Brinsupri, Arikayce |
| Azurity Pharmaceuticals, INC. | $21.53 | 2025 | Alvesco |
| Baxter Healthcare | $21.34 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $13.89 | 2025 | |
| Alk-Abello, INC | $12.92 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Astorga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.